drugset
Drugs / MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
last change Feb 2008 re-read 9 days ago

MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine

Vaccine

Developed for
fallopian tube cancer · ovarian cancer · primary peritoneal carcinoma
Investigated by
Craig L Slingluff, Jr · National Cancer Institute (NCI)

Trials 1

today NCT00373217 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00373217 Apr 2006 → Feb 2008 fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma Craig L Slingluff, Jr Terminated No outcome recorded Stop: Enrollment

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00373217 ↗
Action Deplete “Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.” NCT00373217 ↗
Modality Vaccine “vaccine therapy comprising synthetic ovarian cancer-associated peptides” NCT00373217 ↗
Route Subcutaneous “Given intradermally or subcutaneously” NCT00373217 ↗